L Lashnews Medical aesthetics sourcing from China
News Sourcing Guide

【Cikarang, We】CelaTox Completes Production Facility in Indonesia with 394 Billion Won Investment, Producing Indonesia’s First Botulinum Toxin

Jul 21, 2026

Editor’s Note

**Editor’s Note:** Daewoong Group’s CelaTox BioPharma has completed Indonesia’s first botulinum toxin production facility in Cikarang, West Java, securing GMP certification from BPOM. This milestone strengthens local bio-industry capabilities and establishes a global production base.

Facility Completion and GMP Certification

Daewoong Group affiliate CelaTox BioPharma has completed the construction of a biopharmaceutical production facility in Cikarang, West Java, Indonesia. This marks the establishment of Indonesia’s first botulinum toxin production facility, enabling Daewoong Group to foster the local bio-industry and secure a global production base.
According to local media on the 21st, the Indonesian Food and Drug Supervisory Agency (BPOM) granted Good Manufacturing Practice (GMP) certification to CelaTox BioPharma at the completion ceremony held the previous day.

None
“Daewoong Group’s investment of 4.7 trillion rupiah (approximately 394 billion won) is a strategic milestone for the development of Indonesia’s biopharmaceutical industry,” said BPOM Head Taruna Ikrar. “BPOM will actively support investment expansion while thoroughly ensuring that all products meet international standards of safety, quality, and efficacy.”
Company Background and Facility Capabilities

Established in Indonesia in 2022, CelaTox BioPharma is a biopharmaceutical company specializing in the R&D and production of botulinum toxin type A for the medical aesthetics field. The company has built an integrated biopharmaceutical ecosystem centered around the Cikarang production plant and the Depok R&D center. The newly completed facility is Indonesia’s first dedicated botulinum toxin production plant, with an annual capacity of 6.5 million vials. It incorporates automated production systems, aseptic manufacturing processes, a Quality Management System (QMS), and cold chain logistics to ensure the quality and stability of biopharmaceuticals.

None
“Obtaining GMP certification is a significant achievement, demonstrating that CelaTox’s manufacturing facilities and quality management systems meet regulatory standards,” said Cho Young-hoon, CEO of CelaTox BioPharma. “We will organically link R&D, production, and global business operations, and continue to expand local talent development and investment in international-level manufacturing technology to contribute to the development of Indonesia’s biopharmaceutical industry.”
Future Plans and Government Expectations

The Indonesian government expects CelaTox’s production facility to serve as a catalyst for strengthening the national healthcare industry’s competitiveness and the foundation for biopharmaceutical self-sufficiency.

None

Currently, ‘CelaToxin’ is undergoing clinical development for commercialization both domestically and internationally. CelaTox BioPharma plans to leverage Daewoong Group’s global network to develop Indonesia into a global production hub for bio-aesthetic pharmaceuticals.

Full article: View original |
⏰ Published on: July 21, 2026